Literature DB >> 33948899

Genipin Attenuates Tau Phosphorylation and Aβ Levels in Cellular Models of Alzheimer's Disease.

Meiting Li1, Nan Cai1,2, Liang Gu1,2, Lijun Yao1, Decheng Bi1, Weishan Fang3, Zhijian Lin4, Yan Wu5, Hong Xu1, Hui Li1, Zhangli Hu1, Xu Xu6.   

Abstract

Alzheimer's disease (AD) is a devastating brain disorder characterized by neurofibrillary tangles and amyloid plaques. Inhibiting Tau protein and amyloid-beta (Aβ) production or removing these molecules is considered potential therapeutic strategies for AD. Genipin is an aglycone and is isolated from the extract of Gardenia jasminoides Ellis fruit. In this study, the effect and molecular mechanisms of genipin on the inhibition of Tau aggregation and Aβ generation were investigated. The results showed that genipin bound to Tau and protected against heparin-induced Tau fibril formation. Moreover, genipin suppressed Tau phosphorylation probably by downregulating the expression of CDK5 and GSK-3β, and activated mTOR-dependent autophagy via the SIRT1/LKB1/AMPK signaling pathway in Tau-overexpressing cells. In addition, genipin decreased Aβ production by inhibiting BACE1 expression through the PERK/eIF2α signaling pathway in N2a/SweAPP cells. These data indicated that genipin could effectively lead to a significant reduction of phosphorylated Tau level and Aβ generation in vitro, suggesting that genipin might be developed into an effective therapeutic complement or a potential nutraceutical for preventing AD.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-beta; Autophagy; Genipin; Tau protein

Mesh:

Substances:

Year:  2021        PMID: 33948899     DOI: 10.1007/s12035-021-02389-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  37 in total

1.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

Authors:  Serge Gauthier; Howard H Feldman; Lon S Schneider; Gordon K Wilcock; Giovanni B Frisoni; Jiri H Hardlund; Hans J Moebius; Peter Bentham; Karin A Kook; Damon J Wischik; Bjoern O Schelter; Charles S Davis; Roger T Staff; Luc Bracoud; Kohkan Shamsi; John M D Storey; Charles R Harrington; Claude M Wischik
Journal:  Lancet       Date:  2016-11-16       Impact factor: 79.321

2.  Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo.

Authors:  Erin E Congdon; Jessica W Wu; Natura Myeku; Yvette H Figueroa; Mathieu Herman; Paul S Marinec; Jason E Gestwicki; Chad A Dickey; W Haung Yu; Karen E Duff
Journal:  Autophagy       Date:  2012-04-01       Impact factor: 16.016

3.  Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model.

Authors:  Cui Lv; Lei Wang; Xiaoli Liu; Shijun Yan; Shirley ShiDu Yan; Yongyan Wang; Wensheng Zhang
Journal:  Neuropharmacology       Date:  2014-09-28       Impact factor: 5.250

Review 4.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Authors:  Justin M Long; David M Holtzman
Journal:  Cell       Date:  2019-09-26       Impact factor: 41.582

5.  Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced alzheimer rat model.

Authors:  Chong Gao; Yueze Liu; Yuanhong Jiang; Jianming Ding; Lin Li
Journal:  Brain Pathol       Date:  2014-02-12       Impact factor: 6.508

Review 6.  Potential role of genipin in cancer therapy.

Authors:  Muthu K Shanmugam; Hongyuan Shen; Feng Ru Tang; Frank Arfuso; Mohanraj Rajesh; Lingzhi Wang; Alan Prem Kumar; Jinsong Bian; Boon Cher Goh; Anupam Bishayee; Gautam Sethi
Journal:  Pharmacol Res       Date:  2018-05-24       Impact factor: 7.658

7.  A phase II trial of tideglusib in Alzheimer's disease.

Authors:  Simon Lovestone; Mercè Boada; Bruno Dubois; Michael Hüll; Juha O Rinne; Hans-Jürgen Huppertz; Miguel Calero; María V Andrés; Belén Gómez-Carrillo; Teresa León; Teodoro del Ser
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

Authors:  L Serenó; M Coma; M Rodríguez; P Sánchez-Ferrer; M B Sánchez; I Gich; J M Agulló; M Pérez; J Avila; C Guardia-Laguarta; J Clarimón; A Lleó; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2009-06-10       Impact factor: 5.996

9.  Tau protein aggregation is associated with cellular senescence in the brain.

Authors:  Nicolas Musi; Joseph M Valentine; Kathryn R Sickora; Eric Baeuerle; Cody S Thompson; Qiang Shen; Miranda E Orr
Journal:  Aging Cell       Date:  2018-10-11       Impact factor: 9.304

Review 10.  Translating the biology of aging into novel therapeutics for Alzheimer disease.

Authors:  Yuko Hara; Nicholas McKeehan; Howard M Fillit
Journal:  Neurology       Date:  2018-12-07       Impact factor: 9.910

View more
  1 in total

Review 1.  Exploring the Therapeutic Potential of Phytochemicals in Alzheimer's Disease: Focus on Polyphenols and Monoterpenes.

Authors:  Ilaria Piccialli; Valentina Tedeschi; Lucia Caputo; Stefano D'Errico; Roselia Ciccone; Vincenzo De Feo; Agnese Secondo; Anna Pannaccione
Journal:  Front Pharmacol       Date:  2022-05-04       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.